4YL Stock Overview
Engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Nanoform Finland Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.91 |
| 52 Week High | €2.28 |
| 52 Week Low | €0.91 |
| Beta | 0.67 |
| 1 Month Change | -17.30% |
| 3 Month Change | -22.76% |
| 1 Year Change | -54.80% |
| 3 Year Change | -74.43% |
| 5 Year Change | n/a |
| Change since IPO | -79.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4YL | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -2.8% | -0.5% | 0.5% |
| 1Y | -54.8% | -5.5% | 14.4% |
Return vs Industry: 4YL underperformed the German Life Sciences industry which returned -5.6% over the past year.
Return vs Market: 4YL underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| 4YL volatility | |
|---|---|
| 4YL Average Weekly Movement | 8.2% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 4YL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 4YL's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 181 | Edward Haeggstrom | www.nanoform.com |
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and flexible dosage forms of nanoformed drug substances. It also offers STARMAP, an online platform to pick winners among candidate molecules for CESS powered nanoforming.
Nanoform Finland Oyj Fundamentals Summary
| 4YL fundamental statistics | |
|---|---|
| Market cap | €80.40m |
| Earnings (TTM) | -€23.43m |
| Revenue (TTM) | €3.66m |
22.0x
P/S Ratio-3.4x
P/E RatioIs 4YL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4YL income statement (TTM) | |
|---|---|
| Revenue | €3.66m |
| Cost of Revenue | €551.98k |
| Gross Profit | €3.11m |
| Other Expenses | €26.54m |
| Earnings | -€23.43m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 20, 2025
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 84.93% |
| Net Profit Margin | -639.69% |
| Debt/Equity Ratio | 0% |
How did 4YL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 07:56 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Nanoform Finland Oyj is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Lars Hevreng | Danske Bank |
| Sami Sarkamies | Danske Bank |
| Christian Glennie | Stifel, Equities Research |